𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease

✍ Scribed by T. Müller; C. Erdmann; S. Muhlack; D. Bremen; H. Przuntek; O. Goetze; D. Woitalla

Publisher
Springer
Year
2006
Tongue
English
Weight
106 KB
Volume
113
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quality of life in early Parkinson's dis
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
✍ Victor S.C. Fung; Lilie Herawati; Ying Wan 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double‐blind study. On

Genetic polymorphism of catechol-O-methy
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's disease
✍ Manuela Contin; Paolo Martinelli; Mirella Mochi; Roberto Riva; Fiorenzo Albani; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract We explored the potential effect of catechol‐__O__‐methyltransferase (COMT) genetic polymorphism on the pharmacokinetics and pharmacodynamics of a standard oral dose of levodopa in patients with Parkinson's disease (PD). We prospectively collected blood samples for COMT genotyping from

Effect of entacapone, a COMT inhibitor,
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
✍ V. V. Myllylä; K. A. Sotaniemi; A. Illi; K. Suominen; T. Keränen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 563 KB

In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate vari